SCHEMBL422710

SCHEMBL422710

[CH2]CCC(=O)N(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497804 0.83
SCHEMBL497714 0.81 ALDH1A1 (0.58)
SCHEMBL1191256 0.81 ALDH1A1 (0.63)
SCHEMBL5111424 0.80
SCHEMBL1415984 0.79 ALDH1A1 (0.56)
SCHEMBL2537508 0.79 ALDH1A1 (0.56)
SCHEMBL2540699 0.79 ALDH1A1 (0.56)
SCHEMBL7555488 0.79 ALDH1A1 (0.56)
SCHEMBL7558675 0.79 ALDH1A1 (0.56)
SCHEMBL7555162 0.79 ALDH1A1 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3245200-B1 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2021-03-10 EP claimed
US-9981954-B2 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-05-29 US claimed
US-20180002314-A1 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-01-04 US claimed
EP-3245200-A1 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS Boehringer Ingelheim International GmbH (DE) 2017-11-22 EP claimed
WO-2016113168-A1 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-07-21 WO claimed
US-20140343111-A1 DIARYLTHIOHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-20 US claimed
US-8785443-B2 Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof XENOPORT, INC. (US) 2014-07-22 US claimed
WO-2014031901-A1 METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF XENOPORT, INC. (US) 2014-02-27 WO claimed
US-20140057918-A1 Methods of Use for Monomethyl Fumarate and Prodrugs Thereof XENOPORT, INC. (US) 2014-02-27 US claimed
EP-2561871-A1 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer The Regents of The University of California (US) 2013-02-27 EP claimed
WO-2010022177-A2 PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. (US) 2010-02-25 WO claimed
US-6472435-B1 ANTITUMOR ANTIPROLIFERATION AGENT FORMED BY AMIDATION OF CARBOXY ACID WITH AROMATIC AMINE COMPOUND ASTRAZENECA AB (SE) 2002-10-29 US claimed
US-6346633-B1 TERT-AMINOPHENYLESTER OF ACID ASTRAZENECA AB (SE) 2002-02-12 US claimed
EP-1064253-A1 ANTI-TUMOUR AGENTS AstraZeneca AB (SE) 2001-01-03 EP claimed
EP-1064257-A1 ANTI-TUMOUR AGENTS AstraZeneca AB (SE) 2001-01-03 EP claimed
WO-1999048857-A1 ANTI-TUMOUR AGENTS ASTRAZENECA AB (SE) 1999-09-30 WO claimed
WO-1999048860-A1 ANTI-TUMOUR AGENTS ASTRAZENECA AB (SE) 1999-09-30 WO claimed
EP-0337765-B1 ACYLSULFONAMIDE DERIVATIVES OF ALPHA-CARBOCYCLYLTOLUIC ACIDS USED AS LEUKOTRIENE ANTAGONISTS ICI AMERICAS INC. (US) 1992-10-14 EP claimed
US-5095038-A Antiinflammatory, antiallergens ICI AMERICAS INC. (US) 1992-03-10 US claimed
EP-0337765-A2 Acylsulfonamide derivatives of alpha-carbocyclyltoluic acids used as leukotriene antagonists ICI AMERICAS INC. (US) 1989-10-18 EP claimed